Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sonoma Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $1.29 Mil.
Sonoma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sonoma Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sonoma Pharmaceuticals's EV-to-EBIT falls into.
Sonoma Pharmaceuticals's current Enterprise Value is $1.63 Mil.
Sonoma Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.41 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sonoma Pharmaceuticals (SNOA) has a EV-to-EBIT of -1.16 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sonoma Pharmaceuticals and its competitors. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry.
Is Sonoma Pharmaceuticals' EV-to-EBIT too high?
Sonoma Pharmaceuticals' current EV-to-EBIT is -1.16. Based on the distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 682 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 45/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' EV-to-EBIT compare to GELS and APUS?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #999999 out of 682 companies for EV-to-EBIT. This places Sonoma Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 16.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.11, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sonoma Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sonoma Pharmaceuticals's current EV-to-EBIT is -1.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals (SNOA) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.52, compared to a current price of $1.30 — trading 14.5% below its estimated fair value. The current EV-to-EBIT is -1.16. Sonoma Pharmaceuticals' overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sonoma Pharmaceuticals (SNOA), the current EV-to-EBIT is -1.16 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sonoma Pharmaceuticals (SNOA) Overvalued in 2026?
Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued.
The current stock price of $1.30 is trading 14.5% below its estimated GF Value™ of $1.52.
GuruFocus considers Sonoma Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for SNOA:
EV-to-EBIT: -1.16
GF Value™: $1.52 vs. price of $1.30 (14.5% below fair value)
No single metric tells the full story. See the SNOA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
45GF Score
Get the complete analysis for SNOA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNOA has been successfully added to your 
